keyword
MENU ▼
Read by QxMD icon Read
search

Plaque psoriasis

keyword
https://www.readbyqxmd.com/read/28541985/new-injectable-drug-treats-moderate-to-severe-plaque-psoriasis
#1
Diane S Aschenbrenner
No abstract text is available yet for this article.
June 2017: American Journal of Nursing
https://www.readbyqxmd.com/read/28540870/atorvastatin-as-adjunctive-therapy-for-chronic-plaque-type-psoriasis-versus-betamethasone-valerate-alone-a-randomized-double-blind-placebo-controlled-trial
#2
Sharlene Helene H Chua, Giselle Marie S Tioleco, Carmela Augusta F Dayrit, Winlove P Mojica, Belen L Dofitas, Lorna F Frez
BACKGROUND: Psoriasis is a T helper 1 cell-mediated chronic inflammation. Statins have been found to have anti-inflammatory and immunomodulatory effects targeting T helper 1 cells and thus, are being investigated as treatments for psoriasis. AIMS: To investigate the efficacy and safety of atorvastatin as adjunctive treatment for mild to moderate chronic plaque psoriasis; and the impact of atorvastatin on quality of life. The study also aimed to correlate the beneficial effects of atorvastatin with its lipid-lowering effects...
May 23, 2017: Indian Journal of Dermatology, Venereology and Leprology
https://www.readbyqxmd.com/read/28538228/glycemic-control-in-the-treatment-of-psoriasis
#3
Wilfred Ip, Mark G Kirchhof
Psoriasis is a common chronic inflammatory skin disease that manifests as scaly erythematous plaques as a consequence of keratinocyte hyperproliferation and inflammation. It is commonly associated with diabetes, obesity, and the metabolic syndrome. While there are numerous approved treatment options available, they have limitations including availability, toxicities such as immunosuppression, and high cost. There is increasing evidence to suggest that several hypoglycemic agents used in the treatment of type 2 diabetes, including glucagon-like peptide-1 receptor agonists, dipeptidyl peptidase-4 inhibitors, thiazolidinediones and biguanides, exert beneficial effects in psoriasis...
May 25, 2017: Dermatology: International Journal for Clinical and Investigative Dermatology
https://www.readbyqxmd.com/read/28537868/psoriasis-mimicking-mycosis-fungoides-clinically
#4
Adam M Vaudreuil, Christopher M Stroud, Sylvia Hsu
Psoriasis is a complex, chronic immune-mediated inflammatory disease that most commonly presents as well-demarcated erythematous plaques with micaceous scale, affecting roughly 3-4% of the US population [1-4]. Clinically, lesions are often well demarcated thick, scaly, erythematous plaques, characteristically located on the extensor surfaces, such as elbows and knees [1]. In most cases, clinical impression is sufficient to diagnose psoriasis. However, sometimes psoriasis can mimic other cutaneous disorders and biopsy may be warranted to discover the diagnosis...
May 15, 2017: Dermatology Online Journal
https://www.readbyqxmd.com/read/28537863/severe-pellagra-masked-by-concurrent-plaque-psoriasis-a-case-report-of-a-hidden-diagnosis
#5
Elizabeth A Wang, Jason Kao, Michelle Y Cheng, Chelsea Ma, Soneet Dhillon, Thomas Konia, Emanual Maverakis, Cindy J Chambers
Despite characteristic features, psoriasis can mimic other dermatologic conditions, such as seborrheic dermatitis, lichen simplex chronicus, and certain nutritional deficiencies such as pellagra. We present a patient with a longstanding history of severe plaque psoriasis who presented with disfiguring scaly plaques involving greater than 80% body surface area. The patient's disease was minimally responsive to multiple therapies. Repeat punch biopsies demonstrated parakeratosis, psoriasiform hyperplasia, and dilated blood vessels consistent with psoriasis...
May 15, 2017: Dermatology Online Journal
https://www.readbyqxmd.com/read/28537861/use-of-an-oral-phosphodiesterase-4-inhibitor-apremilast-for-the-treatment-of-chronic-severe-atopic-dermatitis-a-case-report
#6
Benjamin Farahnik, Kourosh Beroukhim, Mio Nakamura, Michael Abrouk, Tian Hao Zhu, Rasnik Singh, Kristina Lee, Tina Bhutani, John Koo, Wilson Liao
Atopic dermatitis (AD) is a common inflammatory dermatosis characterized by pruritus, erythema, induration, and lichenification. Current treatment options for generalized atopic dermatitis are limited and have potentially serious adverse effects, especially in patients with severe, chronic AD who frequently require systemic anti-inflammatory agents. Apremilast, an oral phosphodiesterase-4 inhibitor, was FDA approved in September 2014 for the treatment of moderate-to-severe plaque psoriasis. However, its upstream anti-inflammatory effects, ease of use as an oral agent, and mild side-effect profile make it an interesting treatment option for AD as well...
May 15, 2017: Dermatology Online Journal
https://www.readbyqxmd.com/read/28534602/the-management-of-moderate-to-severe-chronic-plaque-psoriasis
#7
Annalisa Tonini, Salvatore Panduri, Angelo M D'Erme, Francesca Papadia, Marco Romanelli, James G Krueger, Andrea Chiricozzi
Recent approval and marketization of novel treatments have widened the range of therapeutic opportunities for moderate-to-severe psoriasis. In the next years, this panorama will be further enlarged as many other agents, both oral small molecules and biologics, have passed phase III and are expected to be approved, and subsequently marketed, shortly. In spite of this array of therapeutic possibilities, there is still an unmet need for an appropriate treatment in a large number of cases. This review was aimed to describe general principles regarding the therapeutic approach to moderate-severe plaque psoriasis, providing an updated overview of the therapeutic armamentarium that is specifically available in Italy, drug prescribility, and some peculiar limitations for reimbursement defined by our National Health Care System...
May 23, 2017: Giornale Italiano di Dermatologia e Venereologia: Organo Ufficiale, Società Italiana di Dermatologia e Sifilografia
https://www.readbyqxmd.com/read/28522048/itch-intensity-in-moderate-to-severe-plaque-psoriasis-versus-atopic-dermatitis-a-meta-analysis
#8
Kathryn T Shahwan, Alexa B Kimball
No abstract text is available yet for this article.
June 2017: Journal of the American Academy of Dermatology
https://www.readbyqxmd.com/read/28511390/expression-of-angiogenic-factors-in-psoriasis-vulgaris
#9
Lakshna Sankar, Dhanalakshmi Arumugam, Sudha Boj, Priyanka Pradeep
INTRODUCTION: Psoriasis is a chronic inflammatory skin disease characterized by epidermal hyperproliferation, abnormal differentiation and inflammatory infiltration in the dermis. The dermal microvascular expansion associated with abnormal orientation and dilatation of capillaries in the biopsies of the psoriatic skin suggest that the disease is dependent on angiogenesis. AIM: To analyze and compare the immunohistochemical expression of angiogenic factors - Vascular Endothelial Growth Factor (VEGF), von Willebrand Factor (vWF) and CD 34 in skin biopsies of psoriasis cases with control skin samples; and to correlate the expression of angiogenic factors with Psoriasis Area and Severity Clinical Index (PASI SCORE)...
March 2017: Journal of Clinical and Diagnostic Research: JCDR
https://www.readbyqxmd.com/read/28509526/paraoxonases-and-psoriasis-negative-imbalance-of-anti-oxidant-endogenous-mechanisms
#10
Maria Schiattarella, Giuseppina Caiazzo, Roberta DI Caprio, Serena Lembo, Annunziata Raimondo, Fabio Ayala, Nicola Balato, Giuseppe Monfrecola, Giuliana Fortunato, Anna Balato
BACKGROUNG: Numerous reports have shown that psoriasis patients are more exposed to lipoprotein peroxidation and to a decrease in the activity of paraoxonase (PON)1, an anti-oxidant and anti-inflammatory enzyme. Thus, it has been suggested that malfunction of the anti-oxidant system and an increased production of reactive oxygen species drive immune inflammatory events, that result in progressive skin cell damage in patients with psoriasis. The PON protein family, including PON1, PON2 and PON3, is one of the most important endogenous defense mechanisms against oxidative stress...
May 16, 2017: Giornale Italiano di Dermatologia e Venereologia: Organo Ufficiale, Società Italiana di Dermatologia e Sifilografia
https://www.readbyqxmd.com/read/28508536/risankizumab-versus-ustekinumab-for-moderate-to-severe-plaque-psoriasis
#11
Massimo Fioranelli, Maria Grazia Roccia, Torello Lotti
No abstract text is available yet for this article.
May 16, 2017: Dermatologic Therapy
https://www.readbyqxmd.com/read/28507492/long-term-treatment-of-chronic-plaque-psoriasis-with-biological-drugs-can-control-platelet-activation-targeting-the-bridge-between-inflammation-and-atherothrombosis
#12
Bartłomiej Kwiek, Joanna Narbutt, Anna Sysa-Jędrzejowska, Andrzej Langner, Aleksandra Lesiak
INTRODUCTION: Platelet activation is elevated in moderate to severe psoriasis, and the reduction in platelet activation during short-term treatment has already been demonstrated. Soluble P-selectin is a well-established marker of platelet activation. AIM: To show whether the long-term treatment of psoriasis with biological drugs can reduce elevated platelet activation. MATERIAL AND METHODS: An observational study of 27 patients with chronic plaque psoriasis, treated with infliximab, adalimumab, etanercept, or ustekinumab for up to 12 months was conducted...
April 2017: Postȩpy Dermatologii i Alergologii
https://www.readbyqxmd.com/read/28504031/topical-0-25-desoximetasone-spray-efficacy-for-moderate-to-severe-plaque-psoriasis-a-randomized-clinical-trial
#13
Mohammed D Saleem, Deborah Negus, Steven R Feldman
BACKGROUND: Traditionally, ointments were the vehicle of choice for psoriasis. Poor adherence of traditional vehicles limits the use of topical corticosteroids. Alternative formulations have gained popularity due to their ease of application, improved adherence, and efficacy. OBJECTIVE: To evaluate the efficacy of topical desoximetasone 0.25% spray formulation in extensive psoriasis. METHODS: This multicenter, double-blinded, randomized trial compared twice daily topical 0...
May 13, 2017: Journal of Dermatological Treatment
https://www.readbyqxmd.com/read/28502609/switching-from-originator-infliximab-to-biosimilar-ct-p13-compared-with-maintained-treatment-with-originator-infliximab-nor-switch-a-52-week-randomised-double-blind-non-inferiority-trial
#14
Kristin K Jørgensen, Inge C Olsen, Guro L Goll, Merete Lorentzen, Nils Bolstad, Espen A Haavardsholm, Knut E A Lundin, Cato Mørk, Jørgen Jahnsen, Tore K Kvien
BACKGROUND: TNF inhibitors have improved treatment of Crohn's disease, ulcerative colitis, spondyloarthritis, rheumatoid arthritis, psoriatic arthritis, and chronic plaque psoriasis, but are expensive therapies. The aim of NOR-SWITCH was to examine switching from originator infliximab to the less expensive biosimilar CT-P13 regarding efficacy, safety, and immunogenicity. METHODS: The study is a randomised, non-inferiority, double-blind, phase 4 trial with 52 weeks of follow-up...
May 11, 2017: Lancet
https://www.readbyqxmd.com/read/28498006/serum-ykl-40-as-a-potential-biomarker-of-inflammation-in-psoriasis
#15
A Baran, H Myśliwiec, M Szterling-Jaworowska, P Kiluk, M Świderska, I Flisiak
OBJECTIVE: YKL-40 is an inflammatory glycoprotein associated with atherosclerosis, cardiovascular disease, diabetes or metabolic syndrome which are common comorbidities in psoriasis. The aim of the study was to assess serum YKL-40 level in psoriasis and elucidate possible associations with disease activity, inflammatory or metabolic parameters and treatment. METHODS: A total of 37 individuals with active plaque-type psoriasis and 15 healthy controls were enrolled...
May 12, 2017: Journal of Dermatological Treatment
https://www.readbyqxmd.com/read/28494683/what-is-clearance-worth-patients-stated-risk-tolerance-for-psoriasis-treatments
#16
Angelyn O Fairchild, Shelby D Reed, F Reed Johnson, Greg Anglin, Anne M Wolka, Rebecca A Noel
PURPOSE: The purpose of this study was to provide quantitative evidence of patients' tolerance for therapeutic risks associated with psoriasis treatments that could offer psoriasis improvements beyond the PASI 75 benchmark. MATERIALS AND METHODS: We used a discrete-choice experiment in which respondents chose between competing psoriasis treatments characterized by benefits (ie, reduced plaque severity, reduced plaque area), risks (ie, 10-year risk of tuberculosis, 10-year risk of death from infection), and treatment regimen...
May 12, 2017: Journal of Dermatological Treatment
https://www.readbyqxmd.com/read/28494626/desoximetasone-0-25-spray-adrenal-suppression-and-efficacy-in-extensive-plaque-psoriasis
#17
Mohammed D Saleem, Steven R Feldman
BACKGROUND: In extensive psoriasis, topical corticosteroids are generally only used to supplement phototherapy and systemic therapy. Spray formulations are easier than other vehicle preparations to apply and may be an option for treating extensive psoriasis. OBJECTIVE: To evaluate the potential for hypothalamic-pituitary-adrenal axis suppression and efficacy of topical desoximetasone 0.25% spray formulation in patients with extensive psoriasis. METHODS: A multicenter, open label, non-randomized, clinical trial was conducted...
May 12, 2017: Journal of Dermatological Treatment
https://www.readbyqxmd.com/read/28493493/neutrophil-lymphocyte-ratio-platelet-lymphocyte-ratio-and-mean-platelet-volume-in-japanese-patients-with-psoriasis-and-psoriatic-arthritis-response-to-therapy-with-biologics
#18
Akihiko Asahina, Naoko Kubo, Yoshinori Umezawa, Hiromi Honda, Koichi Yanaba, Hidemi Nakagawa
Recent studies indicate the presence of systemic inflammation in psoriatic patients, and this inflammatory status is significantly associated with a range of comorbidities. The aim of this study was to evaluate the clinical significance of novel inflammatory biomarkers, neutrophil-lymphocyte ratio (NLR), platelet-lymphocyte ratio (PLR) and mean platelet volume (MPV) in Japanese patients with plaque-type psoriasis (PsV) and psoriatic arthritis (PsA). One hundred and eighty-six patients with PsV and 50 patients with PsA treated with biologics, including infliximab, adalimumab and ustekinumab, were retrospectively analyzed before and after treatment...
May 11, 2017: Journal of Dermatology
https://www.readbyqxmd.com/read/28493369/efficacy-and-safety-of-secukinumab-in-taiwanese-patients-with-moderate-to-severe-plaque-psoriasis-subanalysis-from-erasure-phase-iii-study
#19
Nan-Lin Wu, Chih-Jung Hsu, Fang-Ju Sun, Tsen-Fang Tsai
The efficacy and safety of secukinumab, a fully human anti-interleukin-17A monoclonal antibody, has been evaluated for moderate to severe plaque psoriasis in global trials which have included a low proportion of Asian subjects. We analyzed the efficacy and safety of secukinumab in Taiwanese patients in a phase III global clinical trial (ERASURE). Fifty-one Taiwanese patients were randomized into s.c. placebo, 150 and 300 mg secukinumab treatment groups. The proportions of patients who achieved 75% or more improvement in Psoriasis Area and Severity Index (PASI-75) at week 12 were 87...
May 11, 2017: Journal of Dermatology
https://www.readbyqxmd.com/read/28490884/narrowband-ultraviolet-b-light-treatment-changes-plasma-concentrations-of-mmp-3-mmp-9-and-timp-3-in-psoriatic-patients
#20
Edyta Katarzyna Głażewska, Marek Niczyporuk, Sławomir Ławicki, Maciej Szmitkowski, Magdalena Donejko, Monika Zajkowska, Grażyna Ewa Będkowska, Andrzej Przylipiak
BACKGROUND: Matrix metalloproteinases (MMPs) and their tissue inhibitors (TIMPs) are thought to be associated with the pathogenesis and spread of psoriatic disease. This study was designed to investigate the plasma levels of MMP-3, MMP-9 and TIMP-3 in plaque psoriasis patients prior to and following a course of ultraviolet B narrowband treatment with respect to disease advancement. METHODS: Plasma samples of 49 patients suffering from plaque psoriasis and 40 healthy volunteers were evaluated...
2017: Therapeutics and Clinical Risk Management
keyword
keyword
82378
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"